Effects of statin treatment and withdrawal on angiotensin II-induced phosphorylation of p38 MAPK and ERK1/2 in cultured vascular smooth muscle cells

Biochemical and Biophysical Research Communications

Volumn 353, Issue 1, 2007, Pages 11-17

  Tristano, Antonio G ^a   Castejon, Ana M ^a   Castro, Amy ^a   Cubeddu, Luigi X ^a  

^a Health Professions Division   (United States)

Author keywords

Angiotensin II; Mitogen activated protein kinases; Statin withdrawal; Statins; Vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN II; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SIMVASTATIN; STATINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR RISK; CELL CULTURE; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; ENZYME PHOSPHORYLATION; EXPOSURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REBOUND; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33845633367     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.11.044     Document Type: Article

References (39)

1. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., and Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333 (1995) 1301-1307
2. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., and Gotto Jr. A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet 344 (1994) 1383-1389.
4. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Trial Investigators. N. Engl. J. Med. 335 (1996) 1001-1009
5. LIPID Investigators. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, N. Engl. J. Med. 339 (1998) 1349-1357.
6. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., and Stern T. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
7. Laufs U., Fata V.L., and Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J. Biol. Chem. 272 (1997) 31725-31729
8. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., and Lamas S. Effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cell. J. Clin. Invest. 101 (1998) 2711-2719
9. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., and Liao J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA 95 (1998) 8880-8885
10. Wassmann S., Laufs U., Baumer A.T., Muller K., Konkol C., Sauer H., Bohm M., and Nickening G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol. Pharmacol. 59 (2001) 646-654
11. Kalinowski L., Dobrucki L.W., Brovkovych V., and Malinski T. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 105 (2002) 933-938
12. Thomas M., and Mann J. Increased thrombotic vascular events after change of statin. Lancet 352 (1998) 1830-1831
13. Heeschen C., Hamm C.W., Laufs U., Snapinn S., Bohm M., and White H.D. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 105 (2002) 1446-1452
14. Spencer F.A., Fonarow G.C., Frederick P.D., Wright R.S., Every N., Goldberg R.J., Gore J.M., Dong W., Becker R.C., and French W. National Registry of Myocardial Infarction. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction. Arch. Intern. Med. 164 (2004) 2162-2168
15. Spencer F.A., Allegrone J., Goldberg R.J., Gore J.M., Fox K.A., Granger C.B., Mehta R.H., and Brieger D. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann. Intern. Med. 140 (2004) 857-866
16. Cubeddu L.X., and Seamon M.J. Statin withdrawal: clinical implications and molecular mechanisms. Pharmacotherapy 26 (2006) 1288-1296
17. Kaesemeyer W.H., Caldwell R.B., Huang J., and Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J. Am. Coll. Cardiol. 33 (1999) 234-241
18. Wagner A.H., Kohler T., Ruckschloss U., Just I., and Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 61-69
19. Laufs U., Endres M., Custodis F., Gertz K., Nickenig G., Liao J.K., and Bohm M. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 102 (2000) 3104-3110
20. Vecchione C., and Brandes R.P. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ. Res. 91 (2002) 173-179
21. Brandes R.P., Beer S., Ha T., and Busse R. Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1794-8000
22. Takahashi T., Taniguchi T., Okuda M., Takahashi A., Kawasaki S., Domoto K., Taguchi M., Ishikawa Y., and Yokoyama M. Participation of reactive oxygen intermediates in the angiotensin II-activated signaling pathways in vascular smooth muscle cells. Ann. NY Acad. Sci. 902 (2000) 283-287
23. Ushio-Fukai M., Alexander R.W., Akers M., Yin Q., Fujio Y., Walsh K., and Griendling K.K. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J. Biol. Chem. 274 (1999) 22699-22704
24. Touyz R.M., Cruzado M., Tabet F., Yao G., Salomon S., and Schiffrin E.L. Redox-dependent MAP kinase signaling by Ang II in vascular smooth muscle cells: role of receptor tyrosine kinase transactivation. Can. J. Physiol. Pharmacol. 81 (2003) 159-167
25. Mii S., Khalil R.A., Morgan K.G., Ware J.A., and Kent K.G. Mitogen-activated protein kinase and proliferation of human vascular smooth muscle cells. Am. J. Physiol. 270 (1996) H142-H150
26. Force T., and Bonventre J.V. Growth factors and mitogen-activated protein kinases. Hypertension 31 (1998) 152-161
27. Touyz R.M., and Schiffrin E.L. Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension 34 (1999) 976-982
28. Battle T., Arnal J.F., Challah M., and Michel J.B. Selective isolation of rat aortic wall layers and their cell types in culture-application to converting enzyme activity measurement. Tissue Cell 26 (1994) 943-955
29. Rajagopalan S., Kurz S., Münzel T., Tarpey M., Freeman B.A., Griendling K.K., and Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97 (1996) 1916-1923
30. Hahn A.W., Jonas U., Buhler F.R., and Resink T.J. Activation of human peripheral monocytes by angiotensin II. FEBS Lett. 347 (1994) 178-180
31. Kranzhofer R., Schmidt J., Pfeiffer C.A.H., Hagl S., Libby P., and Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1623-1629
32. Matsusaka T., and Ichikawa I. Biological functions of angiotensin and its receptors. Annu. Rev. Physiol. 59 (1997) 395-412
33. Touyz R.M., El Mabrouk M., and Schiffrin E.L. MEK inhibition attenuates Ang II-mediated signaling and contraction in SHR vascular smooth muscle cells. Circ. Res. 84 (1999) 505-515
34. Gertz K., Laufs U., Lindauer U., Nickenig G., Bohm M., Dirnagl U., and Endres M. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 34 (2003) 551-557
35. Park J.K., Muller D.N., Mervaala E.M., Dechend R., Fiebeler A., Schmidt F., Bieringer M., Schafer O., Lindschau C., Schneider W., Ganten D., Luft F.C., and Haller H. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int. 58 (2000) 1420-1430
36. Takata R., Fukasawa S., Hara T., Nakajima H., Yamashina A., Yanase N., and Mizuguchi J. Cerivastatin-induced apoptosis of human aortic smooth muscle cells through partial inhibition of basal activation of extracellular signal-regulated kinases. Cardiovasc. Pathol. 13 (2004) 41-48
37. Horiuchi M., Cui T.-X., Li Z., Li J.-M., Nakagami H., and Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 107 (2003) 106-112
38. Liao D.F., Duff J.L., Daum G., Pelech S.L., and Berk B.C. Angiotensin II stimulates MAP kinase activity in vascular smooth muscle cells, role of rat. Circ. Res. 79 (1996) 1007-1014
39. Liao D.F., Monia B., Dean N., and Berk B.C. Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. J. Biol. Chem. 272 (1997) 6146-6150